RTQ1.F AVACTA GROUP PLC LS-10

Healthcare Biotechnology Frankfurt Exchange
0.7350 EUR
Close of Nov 12, 2026
0.5550 1.04
Market cap
EUR 322M
P/E
-
P/B
61.22x
ROE
-1,559.5%
Dividend yield
-
Fundamental score
-

Ratios use the latest price and the fiscal year ending Dec 2025.

Is RTQ1.F undervalued?

Graham number

The Graham number of AVACTA GROUP PLC LS-10 cannot be estimated reliably (it needs positive earnings and book value).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

AVACTA GROUP PLC LS-10 fundamental analysis

No fundamental analysis for AVACTA GROUP PLC LS-10 yet.

AVACTA GROUP PLC LS-10 stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About AVACTA GROUP PLC LS-10

Avacta Group Plc, together with its subsidiaries, engages in the development of cancer therapies in the United Kingdom, South Korea, and internationally. The company's lead product candidate is AVA6000, a peptide drug conjugate form of doxorubicin, which is an approved cancer drug with known severe toxicities. It also develops AVA6103, a peptide drug conjugate technology designed to deliver exatecan, a potent topoisomerase I inhibitor directly to tumors while limiting the ex…

Full company profile